Clyman RI Patent ductus arteriosus, its treatments, and the risks of pulmonary morbidity. Semin Perinatol. 2018 Jun;42(4):235-242. doi: 10.1053/j.semperi.2018.05.006. Epub 2018 May 10. Review.
Cohen S, Bueno de Mesquita M, Mimouni FB Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol. 2015 Aug;80(2):200-8. doi: 10.1111/bcp.12619. Epub 2015 Jun 11. Review.
Hassall E Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr. 2005 Mar;146(3 Suppl):S3-12. Review.
Kalikkot Thekkeveedu R, Guaman MC, Shivanna B Bronchopulmonary dysplasia: A review of pathogenesis and pathophysiology. Respir Med. 2017 Nov;132:170-177. doi: 10.1016/j.rmed.2017.10.014. Epub 2017 Oct 24. Review.
Nagiub M, Kanaan U, Simon D, Guglani L Risk Factors for Development of Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Systematic Review and Meta-Analysis. Paediatr Respir Rev. 2017 Jun;23:27-32. doi: 10.1016/j.prrv.2016.11.003. Epub 2016 Nov 22. Review.
Pérez Tarazona S, Solano Galán P, Bartoll Alguacil E, Alfonso Diego J Bronchopulmonary dysplasia as a risk factor for asthma in school children and adolescents: A systematic review. Allergol Immunopathol (Madr). 2018 Jan - Feb;46(1):87-98. doi: 10.1016/j.aller.2017.02.004. Epub 2017 Jun 28. Review.
Vandenplas Y, Goyvaerts H, Helven R, Sacre L Gastroesophageal reflux, as measured by 24-hour pH monitoring, in 509 healthy infants screened for risk of sudden infant death syndrome. Pediatrics. 1991 Oct;88(4):834-40.
Gastroesophageal Reflux Poses a Potential Risk for Late Complications of BPD: A Prospective Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
